Beste apotheek van Nederland

Mealy N E. Alprostadil cream. Drugs of the Future
2004;29(6):626-627.
Mealy N E, Bayes M. PT-141. Drugs of the Future
2004;29(11):1177
Mehdiyev T V. Intracavernous injection probe of vasoactive
preparations in the diagnosis of erectile dysfunctions in patients
with diabetes mellitus. Azerbaidzhanskii Meditsinskii Zhurnal
2002;(pp 17-19):-19.
Meinhardt W, de la, Fuente R B et al. Prostaglandin E1 with
phentolamine for the treatment of erectile dysfunction. Int J
Impot Res 1996;8(1):5-7.
Meinhardt W, Nijeholt A A, Kropman R F et al. Comparison of
a mixture of papaverine, phentolamine and prostaglandin E1
with other intracavernous injections. Eur Urol 1994;26(4):319­
321.
Mellinger B C, Fried J J, Darracott Vaughan. Papaverineinduced
penile blood flow acceleration in impotent men
measured by duplex scanning. Br J Urol 1990;144(4):897-899.
Merrick G S, Butler W M, Lief J H et al. Efficacy of sildenafil
citrate in prostate brachytherapy patients with erectile
dysfunction. Urology 1999;53(6):1112-1116.
Metawea B, El-Nashar A R, Gad-Allah A et al. Intracavernous
papaverine/phentolamine-induced priapism can be accurately
predicted with color Doppler ultrasonography. Urology
2005;66(4):858-860.
Meyhoff H H, Rosenkilde P, Bodker A. Non-invasive
management of impotence with transcutaneous nitroglycerin. Br
J Urol 1992;69(1):88-90.
Mikhail N. Does Testosterone Have a Role in Erectile
Function?. Am J Med 2006;119373-382.
Millard R J, Stricker P D, Lynch W J et al. Risks of selfinjection
therapy for impotence. Med J Aust 1996;165(2):117­
118.
Miller N, Smolkin M E, Bissonette E et al. Undetectable
prostate specific antigen at 6-12 months: a new marker for early
success in hormonally treated patients after prostate
brachytherapy. Cancer 2005;103(12):2499-2506.
Mills T M, Lewis R W. The role of androgens in the erectile
response: A 1999 perspective. Mol Urol 1999;3(2):75-80.
Mirone V G, Stief C G. Efficacy of apomorphine SL in erectile
dysfunction.[erratum appears in BJU Int 2002 Jan;89(1):140].
[Review] [11 refs]. BJU Int 2001;88(Suppl 3):25-29.
Mirone V, Imbimbo C, Fabrizio F et al. Ketanserin plus
prostaglandin E1 (PGE-1) as intracavernosal therapy for patients
with erectile dysfunction unresponsive to PGE-1 alone. Br J
Urol 1996;77(5):736-739.
Mirone V, Palmieri A, Cucinotta D et al. Flexibledose
vardenafil in a community-based population of
men affected by erectile dysfunction: a 12-week openlabel,
multicenter trial. Br J Sex Med 2005;2(6):842­
847.
Mittleman M A, Glasser D B, Orazem J. Clinical trials
of sildenafil citrate (Viagra) demonstrate no increase
in risk of myocardial infarction and cardiovascular
death compared with placebo. Int J Clin Pract
2003;57(7):597-600.
Mittleman M A, Maclure M, Glasser D B. Evaluation
of acute risk for myocardial infarction in men treated
with sildenafil citrate. Am J Cardiol 2005;96(3):443­
446.
Moemen M N, Hamed H A, Kamel I I et al. Clinical
and sonographic assessment of the side effects of
intracavernous injection of vasoactive substances. Int J
Impot Res 2004;16(2):143-145.
Moncada I, Jara J, Subira D et al. Efficacy of
sildenafil citrate at 12 hours after dosing: re-exploring
the therapeutic window. Eur Urol 2004;46(3):357-360.
Montorsi F, Althof S E. Partner responses to sildenafil
citrate (Viagra) treatment of erectile dysfunction.
Urology 2004;63(4):762-767.
Montorsi F, McCullough A. Efficacy of sildenafil
citrate in men with erectile dysfunction following
radical prostatectomy: A systematic review of clinical
data. Br J Sex Med 2005;2(5):658-667.
Montorsi F, Althof S E, Sweeney M et al. Treatment
satisfaction in patients with erectile dysfunction
switching from prostaglandin E(1) intracavernosal
injection therapy to oral sildenafil citrate. Int J Impot
Res 2003;15(6):444-449.
Montorsi F, Briganti A, Salonia A et al. Can
Phosphodiesterase Type 5 Inhibitors Cure Erectile
Dysfunction?. Eur Urol 2006;49(6):979-986.
Montorsi F, Guazzoni G, Barbieri L et al. The effect
of intracorporeal injection plus genital and audiovisual
sexual stimulation versus second injection on penile
color Doppler sonography parameters. Br J Urol
1996;155(2):536-540.
Montorsi F, Guazzoni G, Bergamaschi F et al.
Effectiveness and safety of multidrug intracavernous
therapy for vasculogenic impotence. Urology
1993;42(5):554-558.
Montorsi F, Guazzoni G, Bergamaschi F et al. Fourdrug
intracavernous therapy for impotence due to
corporeal veno-occlusive dysfunction. Br J Urol
1993;149(5 Pt 2):1291-1295.
D-175